A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Clinical trial NCT02906202 · COMPLETED

Trial details

NCT number: NCT02906202
Sponsor: Genetix Biotherapeutics Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Beta-Thalassemia

Start date: 2016-08-08
Primary completion: 2022-03-31
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.